Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 6/2018

19.04.2018 | Rhinology

Influence of MP 29-02 on ciliary beat frequency in human epithelial cells in vitro

verfasst von: D. Häussler, J. U. Sommer, A. Nastev, C. Aderhold, A. Wenzel, B. Kramer, B. A. Stuck, R. Birk

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

MP 29-02, which contains fluticasone propionate and azelastine hydrochloride, is used as a topical nasal application for the treatment of seasonal and perennial allergic rhinitis. Although a multitude of data is available on the clinical symptom reduction and treatment safety of MP 29-02, the effect of MP 29-02 on ciliary beat frequency (CBF) has not been evaluated thus far.

Methods

MP 29-02-containing solution was applied at concentrations of 2.5, 5, 10, and 20% to 14 healthy subjects, and nasal ciliated epithelial cells were then visualized using a phase-contrast microscope. CBF was measured after the application of MP 29-02. For a comparison, fluticasone propionate was used. CBF measurements were then performed for 15 min at 22 °C. Ringer’s solution was applied as a negative control.

Results

MP 29-02 significantly reduced CBF at all the tested concentrations compared with that of the control group within the observation time. At a 2.5% concentration, MP 29-02 significantly reduced CBF from 6.81 Hz (SD ± 1.35 Hz) at baseline to 4.88 Hz (SD ± 1.52 Hz, p < 0.001) after 15 min. In contrast, for fluticasone propionate, a significant reduction was observed only with the 20% concentration after 5, 10, and 15 min.

Conclusions

MP 29-09 significantly reduced CB, with an almost linear relationship between the MP 29-09 concentration and reduction in CBF. For fluticasone propionate, a significant reduction of CBF was observed only at the highest analyzed concentration. The findings have implications for the long-term use of the MP 29-02. Yet, further clinical studies are needed to confirm these results in vivo, especially in patients with seasonal or perennial allergic rhinits.
Literatur
7.
Zurück zum Zitat Bush RK (2004) Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review. Treat Respir Med 3(1):45–57CrossRefPubMed Bush RK (2004) Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review. Treat Respir Med 3(1):45–57CrossRefPubMed
8.
Zurück zum Zitat Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W (2012) MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 33(4):324–332. https://doi.org/10.2500/aap.2012.33.3587 CrossRefPubMed Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W (2012) MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 33(4):324–332. https://​doi.​org/​10.​2500/​aap.​2012.​33.​3587 CrossRefPubMed
11.
Zurück zum Zitat Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, Carr W et al (2013) A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 23(7):495–503PubMed Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, Carr W et al (2013) A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 23(7):495–503PubMed
12.
Zurück zum Zitat Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S (2014) Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract 2(2):179–185. https://doi.org/10.1016/j.jaip.2013.09.019 CrossRefPubMed Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S (2014) Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract 2(2):179–185. https://​doi.​org/​10.​1016/​j.​jaip.​2013.​09.​019 CrossRefPubMed
14.
Zurück zum Zitat Cohen NA (2006) Sinonasal mucociliary clearance in health and disease. Ann Otol Rhinol Laryngol Suppl 196:20–26CrossRefPubMed Cohen NA (2006) Sinonasal mucociliary clearance in health and disease. Ann Otol Rhinol Laryngol Suppl 196:20–26CrossRefPubMed
15.
Zurück zum Zitat Inoue D, Furubayashi T, Ogawara K, Kimura T, Higaki K, Shingaki T, Kimura S et al (2013) In vitro evaluation of the ciliary beat frequency of the rat nasal epithelium using a high-speed digital imaging system. Biol Pharm Bull 36(6):966–973CrossRefPubMed Inoue D, Furubayashi T, Ogawara K, Kimura T, Higaki K, Shingaki T, Kimura S et al (2013) In vitro evaluation of the ciliary beat frequency of the rat nasal epithelium using a high-speed digital imaging system. Biol Pharm Bull 36(6):966–973CrossRefPubMed
19.
Zurück zum Zitat Duchateau GS, Graamans K, Zuidema J, Merkus FW (1985) Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. Laryngoscope 95(7 Pt 1):854–859PubMed Duchateau GS, Graamans K, Zuidema J, Merkus FW (1985) Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. Laryngoscope 95(7 Pt 1):854–859PubMed
21.
Zurück zum Zitat Hee J, Guillerm R (1977) [Mucociliary function and its alteration by certain irritants (author’s transl)]. Bull Eur Physiopathol Respir 13(1):11–25PubMed Hee J, Guillerm R (1977) [Mucociliary function and its alteration by certain irritants (author’s transl)]. Bull Eur Physiopathol Respir 13(1):11–25PubMed
25.
Zurück zum Zitat Klossek JM, Laliberte F, Laliberte MF, Mounedji N, Bousquet J (2001) Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Rhinology 39(1):17–22PubMed Klossek JM, Laliberte F, Laliberte MF, Mounedji N, Bousquet J (2001) Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Rhinology 39(1):17–22PubMed
27.
Zurück zum Zitat Achterrath-Tuckermann U, Saano V, Minker E, Stroman F, Arny I, Joki S, Nuutinen J et al (1992) Influence of azelastine and some selected drugs on mucociliary clearance. Lung 170(4):201–209CrossRefPubMed Achterrath-Tuckermann U, Saano V, Minker E, Stroman F, Arny I, Joki S, Nuutinen J et al (1992) Influence of azelastine and some selected drugs on mucociliary clearance. Lung 170(4):201–209CrossRefPubMed
28.
Zurück zum Zitat Tamaoki J, Chiyotani A, Sakai N, Takeyama K, Konno K (1993) Effect of azelastine on sulphur dioxide induced impairment of ciliary motility in airway epithelium. Thorax 48(5):542–546CrossRefPubMedPubMedCentral Tamaoki J, Chiyotani A, Sakai N, Takeyama K, Konno K (1993) Effect of azelastine on sulphur dioxide induced impairment of ciliary motility in airway epithelium. Thorax 48(5):542–546CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Sisson JH, Stoner JA, Ammons BA, Wyatt TA (2003) All-digital image capture and whole-field analysis of ciliary beat frequency. J Microsc 211(Pt 2):103–111CrossRefPubMed Sisson JH, Stoner JA, Ammons BA, Wyatt TA (2003) All-digital image capture and whole-field analysis of ciliary beat frequency. J Microsc 211(Pt 2):103–111CrossRefPubMed
32.
Zurück zum Zitat Team RC (2013) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing Team RC (2013) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing
35.
Zurück zum Zitat Weiner JM, Abramson MJ, Puy RM (1998) Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 317(7173):1624–1629CrossRefPubMedPubMedCentral Weiner JM, Abramson MJ, Puy RM (1998) Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 317(7173):1624–1629CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Jorissen M, Willems T, De Boeck K (2000) Diagnostic evaluation of mucociliary transport: from symptoms to coordinated ciliary activity after ciliogenesis in culture. Am J Rhinol 14(5):345–352CrossRefPubMed Jorissen M, Willems T, De Boeck K (2000) Diagnostic evaluation of mucociliary transport: from symptoms to coordinated ciliary activity after ciliogenesis in culture. Am J Rhinol 14(5):345–352CrossRefPubMed
39.
Zurück zum Zitat Merkus FW, Verhoef JC, Schipper NG, Marttin E (1998) Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29(1–2):13–38PubMed Merkus FW, Verhoef JC, Schipper NG, Marttin E (1998) Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29(1–2):13–38PubMed
41.
Zurück zum Zitat Pipkorn U, Pukander J, Suonpaa J, Makinen J, Lindqvist N (1988) Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy 18(3):253–259CrossRefPubMed Pipkorn U, Pukander J, Suonpaa J, Makinen J, Lindqvist N (1988) Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy 18(3):253–259CrossRefPubMed
42.
Zurück zum Zitat Laliberte F, Laliberte MF, Lecart S, Bousquet J, Klossec JM, Mounedji N (2000) Clinical and pathologic methods to assess the long-term safety of nasal corticosteroids. French Triamcinolone Acetonide Study Group. Allergy 55(8):718–722CrossRefPubMed Laliberte F, Laliberte MF, Lecart S, Bousquet J, Klossec JM, Mounedji N (2000) Clinical and pathologic methods to assess the long-term safety of nasal corticosteroids. French Triamcinolone Acetonide Study Group. Allergy 55(8):718–722CrossRefPubMed
43.
Zurück zum Zitat Baroody FM, Cheng CC, Moylan B, deTineo M, Haney L, Reed KD, Cook CK et al (2001) Absence of nasal mucosal atrophy with fluticasone aqueous nasal spray. Arch Otolaryngol Head Neck Surg 127(2):193–199CrossRefPubMed Baroody FM, Cheng CC, Moylan B, deTineo M, Haney L, Reed KD, Cook CK et al (2001) Absence of nasal mucosal atrophy with fluticasone aqueous nasal spray. Arch Otolaryngol Head Neck Surg 127(2):193–199CrossRefPubMed
45.
Zurück zum Zitat Verret DJ, Marple BF (2005) Effect of topical nasal steroid sprays on nasal mucosa and ciliary function. Curr Opin Otolaryngol Head Neck Surg 13(1):14–18CrossRefPubMed Verret DJ, Marple BF (2005) Effect of topical nasal steroid sprays on nasal mucosa and ciliary function. Curr Opin Otolaryngol Head Neck Surg 13(1):14–18CrossRefPubMed
Metadaten
Titel
Influence of MP 29-02 on ciliary beat frequency in human epithelial cells in vitro
verfasst von
D. Häussler
J. U. Sommer
A. Nastev
C. Aderhold
A. Wenzel
B. Kramer
B. A. Stuck
R. Birk
Publikationsdatum
19.04.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 6/2018
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-018-4979-3

Weitere Artikel der Ausgabe 6/2018

European Archives of Oto-Rhino-Laryngology 6/2018 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Bilateraler Hörsturz hat eine schlechte Prognose

15.04.2024 Hörsturz Nachrichten

Die Mehrzahl der Menschen mit Hörsturz ist einseitig betroffen, doch auch ein beidseitiger Hörsturz ist möglich. Wie häufig solche Fälle sind und wie sich ihr Verlauf darstellt, hat eine HNO-Expertenrunde aus den USA untersucht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.